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Objectives. This study sought to determine the site of increased
pulmonary vascular resistance (PVR) in primary pulmonary
hypertension by standard bedside hemodynamic evaluation.
Background. The measurement of pulmonary vascular pres-
sures at several levels of flow (Q) allows the discrimination
between active and passive, flow-dependent changes in mean
pulmonary artery pressure (Ppa), and may detect the presence of
an increased pulmonary vascular closing pressure. The determi-
nation of a capillary pressure (Pc*) from the analysis of a Ppa
decay curve after balloon occlusion allows the partitioning of PVR
in an arterial and a (capillary 1 venous) segment. These ap-
proaches have not been reported in primary pulmonary hyperten-
sion.
Methods. Ppa and Pc* were measured at baseline and after an
increase in Q induced either by exercise or by an infusion of
dobutamine, at a dosage up to 8 mg/kg body weight per min, in 11
patients with primary pulmonary hypertension. Reversibility of
pulmonary hypertension was assessed by the inhalation of 20 ppm
nitric oxide (NO), and, in 6 patients, by an infusion of prostacy-
clin.
Results. At baseline, Ppa was 52 6 3 mm Hg (mean value 6
SE), Q 2.2 6 0.2 liters/min per m2, and Pc* 29 6 3 mm Hg.
Dobutamine did not affect Pc* and allowed the calculation of an
averaged extrapolated pressure intercept of Ppa/Q plots of
34 mm Hg. Inhaled NO had no effect. Prostacyclin decreased Pc*
and PVR. Exercise increased Pc* to 40 6 3 mm Hg but did not
affect PVR.
Conclusions. These findings are compatible with a major
increase of resistance and reactivity at the periphery of the
pulmonary arterial tree.
(J Am Coll Cardiol 1998;31:1372–6)
©1998 by the American College of Cardiology
The arterial occlusion technique, initially developed in isolated
perfused lungs (1), has been applied to intact animals and to
patients for the partitioning of pulmonary vascular resistance
(PVR) into an arterial segment and a (capillary 1 venous)
segment (2,3). The method has been used mainly for the
determination of pulmonary capillary pressure (Pc9), but has
been shown to overestimate the “effective” capillary pressure
as measured by the reference isogravimetric method in exper-
imental acute lung injury models (3). There are experimental
data suggesting that the (capillary 1 venous) segment as
determined from single arterial occlusion also includes small
pulmonary arterioles 100 to 150 mm in diameter (4).
Another bedside approach to get a deeper insight into the
nature of PVR is based on the determination of multipoint
mean pulmonary artery pressure (Ppa)/flow (Q) plots. In most
cardiac and pulmonary diseases, Ppa/Q plots are well de-
scribed by a linear approximation, but their extrapolation to
the pressure axis (Pi) may be higher than occluded Ppa (Ppao)
or left atrial pressure (5–8). An increased Pi can be explained
by an increased closing pressure of small pulmonary arterioles
or capillaries, or both (5–8).
The objective of the present study was to test the hypothesis
that pathologic changes at the periphery of the pulmonary
arterial tree increase the Pi of Ppa/Q plots and Pc9 as obtained
by arterial occlusion in patients with primary pulmonary
hypertension. Histologic studies indicate that increased PVR
in these patients is mainly due to a disease of small pulmonary
arteries and arterioles, but the extent of associated pathologic
changes upstream is not known exactly (8). There has been no
previous report on pulmonary vascular pressure/flow relations
or on the partitioning of PVR using the arterial occlusion
method in primary pulmonary hypertension.
Methods
Patients. Ten women 33 to 65 years of age (mean 49) and
one man 62 years of age with primary pulmonary hypertension
gave informed consent to this study, which was approved by the
Ethical Committee of the Erasme University Hospital. The
diagnosis of primary pulmonary hypertension required both
the documentation of pulmonary hypertension, with a Ppa
.25 mm Hg and the absence of the following secondary
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causes: congenital abnormalities of lungs, thorax or dia-
phragm; congenital or acquired valvular or myocardial disease;
pulmonary thromboembolism; obstructive lung disease; inter-
stitial lung disease; pulmonary artery or pulmonary valve
stenosis; pulmonary venous hypertension; central hypoventila-
tion with hypoxemia and hypercapnia; parasitic disease affect-
ing the lungs; sickle cell anemia; and collagen vascular disease.
To exclude secondary pulmonary hypertension an algorithm
was used on the basis of a mandatory chest radiograph,
respiratory function, perfusion lung scan, echocardiogram,
right heart catheterization and measurement of arterial blood
gases (9). Eight of the 10 female patients had previously been
exposed to appetite suppressants, either dexfenfluramine or
compound preparations containing fenfluramine. The one
male patient had liver cirrhosis. None of them were treated
with vasodilators. All were dyspneic, class II to III of the New
York Heart Association classification.
Procedures and measurements. Catheterization of the
right side of the heart was performed without premedication,
with the patient lying supine and breathing room air. A
balloon-tipped flow-directed pulmonary catheter (Model
131H-7F Baxter) was inserted under local anesthesia into an
internal jugular vein and floated under constant pressure wave
monitoring into a pulmonary artery to measure pulmonary
artery pressures, Ppa, Ppao, Pc9 (computed from the Ppa decay
curve), right atrial pressure (Pra) and mixed venous blood
sampling. A small polyethylene catheter was inserted into a
radial or a femoral artery to measure systemic arterial pres-
sures and for arterial blood sampling. Pulmonary and systemic
arterial pressures were measured using Gould Statham P50
transducers (Gould Inc.) connected to a bedside hemodynamic
and electrocardiographic monitoring system (SIRECUST 404,
Siemens, Erlangen, Germany). The pressure transducers were
zero referenced at midchest, and vascular pressures were
measured at end expiration. Heart rate was determined from a
continuously monitored electrocardiographic lead. Q was mea-
sured by thermodilution using injections of 10 ml of 5% cold
dextrose in water and a computer (9520-A, Edwards Labora-
tories) and was calculated as the mean of three determinations.
Arterial and mixed venous blood gases were measured by an
automated analyzer (ABL 2, Radiometer, Copenhagen, Den-
mark) immediately after drawing the samples and corrected
for temperature.
Nitric oxide (NO) was supplied from a pure NO source tank
(Oxhydrique, Machelen, Belgium) and delivered through a
face mask. The inspired fraction of NO was monitored by
chemiluminescence after calibration against standard NO con-
centration (Model 42 chemiluminescence NO-NO2-NOx ana-
lyzer, Thermo Environmental Instruments Inc.).
The pulmonary vascular pressure signals were sampled at
200 Hz using an analog/digital converter (RTI 800, Analog
Device) and stored and analyzed on a personal computer. Pc9
was computed in duplicate from the Ppa decay curves after
inflation of the balloon of the pulmonary artery catheter. For
this measurement the patients were asked to stop breathing at
the end of a normal tidal volume for a period of 8 s. Time zero
was defined as the time when pulmonary arterial pressure
began to deviate from the normal wave. This instant was
chosen because in the clinical setting, pressure is the only
signal usually available for this purpose. The Ppa decay curve
was fitted by an exponential equation on the basis of a least
squares analysis applied to a set of data between 0.2 and 2.0 s
after the occlusion, adjusted for Ppao, and extrapolated back
toward time 0 1 150 ms. This time lag after occlusion
corresponds to the delay from the beginning of occlusion to
zero flow reached in the capillaries (10). A typical Ppa decay
curve with analysis for Pc9 is shown in Figure 1.
Study protocol. As soon as steady-state conditions (stable
heart rate, Psa and Ppa for 20 min) were ensured, a baseline
set of hemodynamic and blood gas measurements was ob-
tained. The measurements were repeated, each of them after a
20-min equilibration period, during the following conditions:
1) pedaling in the supine position without load, 2) rest, 3) an
infusion of dobutamine at the doses of 4 mg/kg body weight per
min and 8 mg/kg per min, 5) rest, 6) 20 ppm of inhaled NO, 7)
rest, and, in six of the patients, 8) an infusion of prostacyclin
(Flolan, Glaxo-Wellcome). Only six patients were tested with
prostacyclin because this drug was not available in Belgium at
the start of the study. For the same reason, in three of these
patients, the prostacyclin measurements were obtained be-
tween 6 and 12 months after the other seven steps of the study
Abbreviations and Acronyms
NO 5 nitric oxide
Pc9 5 pulmonary capillary pressure
Pi 5 extrapolated pressure intercept of Ppa/Q plots
PO2 5 partial pressure of oxygen
Ppa 5 mean pulmonary artery pressure
Ppao 5 pulmonary artery occluded pressure
Pra 5 right atrial pressure
Psa 5 mean systemic arterial pressure
PVR 5 pulmonary vascular resistance
Q 5 pulmonary blood flow
Figure 1. Typical pulmonary artery single-occlusion recording to
estimate effective Pc9 by the extrapolation to 150 ms after the instant
of occlusion (To) of a single exponential fitting of the Ppa decay curve
between 200 ms (T200) and 2,000 ms (T2000) after the occlusion, with
secondary adjustment for mean Ppao.
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protocol, at the start of a continuous prostacyclin infusion as a
bridge to transplantation. Prostacyclin was increased by 2 ng/kg
per min increments every 15 min until intolerable side effects
as defined by a decrease in Psa by .30%, an increase in heart
rate by .30% or nausea, vomiting or headache (11). NO was
given at the dose of 20 ppm, two times the dose previously
shown to offer a maximum pulmonary vasodilating effect in
patients with primary pulmonary hypertension (11). The dose
of dobutamine was chosen to reproduce about the same
increase in Q as exercise, and, on the basis of previous animal
studies (12), unlikely to affect pulmonary vascular tone.
Statistical analysis. Results are expressed as mean value 6
SE. The Ppa/Q coordinates obtained by the infusion of dobut-
amine and by exercise were pooled and analyzed using a
method allowing for mild nonlinearities or state dependent
variability, or both (13) to yield averaged slopes and Pi of two-
or three-point Ppa/Q plots. The blood gases and hemodynamic
data were analyzed by a repeated measures analysis of vari-
ance. When the F ratio of the analysis of variance reached a
p , 0.05 critical level, specific comparisons were made using
modified t tests, that is, t tests computed with the residual
variance of the analysis of variance (14).
Results
The main hemodynamic and blood gas measurements are
summarized in Table 1. At baseline, the hemodynamic and
blood gas profile of the patients was similar to that of
previously reported large series of patients with primary pul-
monary hypertension (9), with very high Ppa, moderately high
Pra, normal Ppao, decreased Q, respiratory alkalosis, moder-
ate arterial hypoxemia and decreased mixed venous partial
pressure of oxygen (PO2). Pc9 was markedly elevated, to a
mean value of 29 mm Hg.
Exercise increased Q by an average of 0.9 liter/min per m2,
increased all vascular pressures including Pc9 and decreased
mixed venous PO2. Pc9 increased more than Ppao (by an
average of 11 and 5 mm Hg, respectively). Pooled exercise-
induced Ppa/Q relations had a slope of 15 mm Hg/liter per min
and a Pi of 22 mm Hg (Fig. 2).
Dobutamine at the dose of 8 mg/kg per min increased Q by
an average of 0.6 liter/min per m2, but had no effect on blood
gases or vascular pressures, except for slight decreases in Psa,
Pra and PVR.
Pooled dobutamine-induced relations had a slope of
8.3 mm Hg/liter per min and a Pi of 34 mm Hg (Fig. 2).
NO 20 ppm had no effect on pulmonary hemodynamics or
blood gases. Individual changes in Ppa and in PVR associated
with inhaled NO ranged respectively from 13 to 210 mm Hg
and from 1258 to 2408 dyneszszcm25zm2.
In six of the patients, (three of them 6 to 12 months after
the initial study) an infusion of prostacyclin 4 to 10 ng/kg per
min had no effect on blood gases, Ppa, Pra or Ppao, but
decreased Pc9, PVR and Psa and increased Q (Table 2).
Individual changes in Ppa and PVR ranged respectively from
15 to 216 mm Hg and from 2310 to 21,288 dynezszcm25zm22.
The effects of dobutamine in these 6 patients were the same as
in the group of 11 patients (not shown).
Discussion
The present results show that in severe primary pulmonary
hypertension, both Pi and Pc9 are increased, suggesting that
the main site of increased resistance is at the periphery of the
pulmonary arterial tree, and possibly is a cause of an increased
closing pressure.
Exercise-induced Ppa/Q relations. Ppa/Q relations, with Q
increased by exercise, had a lower Pi and a higher slope than
Figure 2. Pooled Ppa versus Q relations with Q increased by exercise
(solid circles) or dobutamine (open circles) in 11 patients with primary
pulmonary hypertension. The calculated regressions are represented
by the lines. The extrapolated pressure intercept of the dobutamine-
induced Ppa/Q relation was higher than the extrapolated pressure
intercept of the exercise-induced Ppa/Q relation.
Table 1. Hemodynamic and Blood Gas Responses to Exercise,
Dobutamine and Nitric Oxide in 11 Patients With Primary
Pulmonary Hypertension*
Variables Baseline Exercise Dobutamine Nitric Oxide
Q (liter/min per m2) 2.2 6 0.2 3.1 6 0.4§ 2.8 6 0.2‡ 2.2 6 0.2
Heart rate (beats/min) 82 6 2 102 6 3§ 91 6 4‡ 82 6 3
Psa (mm Hg) 102 6 4 118 6 6§ 92 6 4‡ 101 6 4
PVR
(dyneszszcm25zm2)
1,841 6 240 1,717 6 231 1,560 6 216† 1,825 6 278
Ppa (mm Hg) 52 6 3 67 6 2‡ 56 6 4 50 6 4
Pc9 (mm Hg) 29 6 3 40 6 3§ 29 6 4 27 6 3
Ppao (mm Hg) 10 6 1 15 6 2§ 10 6 1 10 6 1
Pra (mm Hg) 8 6 2 15 6 2§ 5 6 2‡ 7 6 2
pHa 7.47 6 0.01 7.46 6 0.01 7.49 6 0.01 7.47 6 0.01
PaO2 (mm Hg) 64 6 4 60 6 5 68 6 4 61 6 4
PaCO2 (mm Hg) 28 6 1 26 6 1 26 6 1 28 6 2
PvO2 (mm Hg) 35 6 2 28 6 3§ 37 6 1 34 6 1
*Values are expressed as mean value 6 SE. †p , 0.05, ‡p , 0.01, §p , 0.001
versus baseline. Dobutamine was infused at the dose of 8 mg/kg per min, and
nitric oxide inhaled at the dose of 20 ppm. PaCO2 5 arterial PCO2; PaO2 5 arterial
PO2; Pc9 5 effective pulmonary capillary pressure; pHa 5 arterial pH; Ppa 5
mean pulmonary artery pressure; Ppao 5 occluded Ppa; Pra 5 right atrial
pressure; Psa 5 mean systemic arterial pressure; PvO2 5 mixed venous PO2;
PVR 5 pulmonary vascular resistance; Q 5 cardiac output.
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dobutamine-induced Ppa/Q relations. Previously reported
exercise-induced Ppa/Q plots in patients with pulmonary vas-
cular disease or left heart failure frequently presented with
higher than normal slopes and low or even negative Pi (15,16).
A negative Pi is physically impossible and can only be ex-
plained by an increase in Ppa at the highest Q because of
exercise-induced pulmonary vasoconstriction (16). Causes of
pulmonary vasoconstriction at exercise include a decreased
mixed venous PO2 (by 7 mm Hg in our patients) and sympa-
thetic nervous system activation (7).
Dobutamine-induced Ppa/Q relations. We hypothesized
that an infusion of dobutamine to increase Q would be more
likely than exercise to allow us to construct passive Ppa/Q
plots, on the basis of previous animal work suggesting that low
dose dobutamine does not affect pulmonary vascular tone (12).
Infusing dobutamine to increase Q led to Ppa/Q plots with a
very high Pi. An increased Pi can be explained by a pulmonary
vascular closing pressure acting as an effective outflow pressure
higher than left atrial pressure (estimated by Ppao) (5–7). This
explanation is based on a reference Starling resistor model
viewing the pulmonary vasculature as a recruiting system of
parallel units with fixed resistance and a distribution of open-
ing pressures (17). There is an alternative viscoelastic model
(18) that explains a Pi that is higher than left atrial pressure by
an increase in resistance and compliance of small order
arterioles (6). This viscoelastic model was found to be superior
to the Starling resistor model of the pulmonary circulation in
experimental embolic pulmonary hypertension (19). However,
the considerable remodeling, including fibrotic changes seen at
the microscopic examination of pulmonary vessels of patients
with primary pulmonary hypertension (8), is not suggestive of
an increased compliance at the site of increased resistance.
Both the Starling resistor and the viscoelastic models of the
pulmonary circulation predict that Ppa/Q relations with an
increased Pi are due to an increased resistance of small
pulmonary arteries and arterioles at the periphery of the
pulmonary arterial tree.
Effects of inhaled NO and intravenous prostacyclin. In the
present study, pulmonary hypertension was on average not
reversible with inhaled NO. Sitbon et al. (11) showed in a
series of 35 patients with primary pulmonary hypertension that
changes in PVR during NO inhalation or prostacyclin infusion
are closely correlated, and that a maximum pulmonary vaso-
dilation can be obtained with 10 ppm NO. However, in six of
our patients unresponsive to 20 ppm inhaled NO, prostacyclin
decreased PVR by 29% (range 18% to 41%). This change
occurred without significant changes in Ppa, but with a de-
crease in Pc9, indicating that the decrease in PVR was not just
an artifact caused by increased Q (5–7), but truly corresponded
to a decreased pulmonary vascular tone. Nevertheless, none of
our patients was a “high responder” to prostacyclin, as defined
by a .50% decrease in PVR (20). Such a response to
prostacyclin was observed in only 9 of 91 patients with primary
pulmonary hypertension in a recent study (20).
Method of measurement of Pc*. A variety of electrical
analog models and methods of analysis of the pressure decay
curve after pulmonary artery occlusion have been reported for
the estimation of Pc9 as a determinant of fluid filtration and
edema in the lung (1–3). Gilbert and Hakim (10) reported
laser Doppler flow measurements in intact dogs to validate a
Pc9 measurement obtained by a back extrapolation to 152 ms
after the initial change in pulmonary artery pressure of a single
exponential fitting of the pressure decay curve between 0.2 to
2 s. A monoexponential fitting is based on a simple electrical
analog model of a single compartment with a large capillary
compliance between arterial and venous resistances. We mod-
ified this model to provide for a parallel structure of the
pulmonary vascular bed at the level of small resistance arteries,
corresponding to inhomogenous distribution of obstruction
and showed that it still predicts that a monoexponential fitting
gives a reasonable approximation of the Ppa decay curve (21).
Applied to intact normal dogs, the modified model allowed the
calculation of a (capillary 1 venous) component of PVR
;25%, somewhat lower than in several previous studies using
different methods of analysis (21). It is thus unlikely that in the
present study the method of analysis of the Ppa decay curve
would have overestimated Pc9.
Interpretation of increased Pc*. In the present study, Pc9
was markedly increased, to levels that would be expected to
produce hydrostatic lung edema (2,3). However, lung edema is
not a feature of primary pulmonary hypertension (9). Several
studies have shown that the arterial occlusion technique may
overestimate the effective Pc9 as determined by the isogravi-
metric method or the double occlusion technique in diseased
lungs (3). Obstruction of small resistive arteries with 100-mm
glass beads increases Pc9 without changes in capillary pressure
as measured by isogravimetry or by the double arterial and
venous occlusion technique (22,23). Hakim and Kelly (4)
compared pressure measurements with micropuncture, a small
retrograde catheter and arterial and venous occlusion in
isolated perfused dogs lungs and found that the arterial
occlusion technique measures pressure in vessels of a diameter
between 50 and 900 mm, probably on average ;100 mm. We
Table 2. Hemodynamic and Blood Gas Responses to Prostacyclin in
Six Patients
Variable
Baseline
(Mean 6 SD)
Prostacyclin*
(Mean 6 SD)
Q (liter/min per m2) 1.8 6 0.2 2.5 6 0.3‡
Heart rate (beats/min) 87 6 3 91 6 2
Psa (mm Hg) 97 6 7 80 6 6‡
PVR (dynezszcm25zm2) 2,479 6 366 1,718 6 244‡
Ppa (mm Hg) 63 6 3 62 6 3
Pc9 (mm Hg) 37 6 4 32 6 3†
Ppao (mm Hg) 13 6 1 12 6 1
Pra (mm Hg) 11 6 2 11 6 2
pHa 7.47 6 0.01 7.48 6 0.01
PaO2 (mm Hg) 57 6 4 56 6 4
PaCO2 (mm Hg) 27 6 1 24 6 2
PvO2 (mm Hg) 34 6 2 34 6 2
*Prostacyclin was infused at an average dose of 6.8 ng/kg per min (range 4 to
10). †p , 0.05, ‡p , 0.01 versus baseline. Abbreviations as in Table 1.
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therefore believe that Pc9 in our patients reflects an increased
pressure in small resistive arteries and arterioles, rather than
an increased pressure in capillaries. It is of interest that
prostacyclin in our patients decreased Pc9, compatible with an
acute effect at the main site of increased resistance.
Histologic studies have shown that primary pulmonary
hypertension is primarily a disease of the small muscular
pulmonary arteries and arterioles that are ,500 to 1,000 mm in
diameter (8). These vessels present with various combinations
of medial hypertrophy, concentric or eccentric intimal fibrosis
and more complex arteritis, plexiform or dilation lesions, with,
in 30% of cases, in situ thrombosis (8). Both increased Pi and
Pc9 in our patients suggest that these lesions are not associated
with structural changes important enough to increase resis-
tance of larger diameter pulmonary arteries. In addition,
increased Pc9 at exercise appear entirely explained by exercise-
induced vasoconstriction at the site of small resistive arteries.
Previous histologic studies have also shown that 10% of
patients with primary pulmonary hypertension present with
pulmonary veno-occlusive disease (8). These patients are
difficult to distinguish clinically from those with a precapillary
pathologic process. In our series, a histologic examination of
the lungs could be obtained in one of the female patients after
a heart–lung transplantation. The examination disclosed no
venous abnormalities in this patient whose Ppa/Q plots and Pc9
did not deviate from the average values of the group as a
whole. In addition, because of the relative rarity of pulmonary
veno-occlusive disease, we believe it unlikely that the increased
Pc9 in the present study could have been explained by an
increase in venous resistance.
Appetite suppressant drugs. Pulmonary hypertension in
eight of our patients was associated with the intake of appetite
suppressant drugs, mainly fenfluramines. The association be-
tween the intake of these drugs and primary pulmonary
hypertension was recently established by a Western European
case control study (24). The clinical course and histologic
pattern in patients with fenfluramine-associated pulmonary
hypertension do not appear different from those of the other
patients with primary pulmonary hypertension (25). It is thus
unlikely that Ppa/Q characteristics and Pc9 determinations in
our patients would have been affected by previous intake of
fenfluramines.
Conclusions. A recent study reported on the use of pulmo-
nary artery pressure waveform analysis for the differential
diagnosis of proximal versus distal obstruction of the pulmo-
nary arterial tree in severe pulmonary hypertension (26). The
present report shows that standard bedside hemodynamic
evaluation with measurements at variable cardiac output and
analysis of pulmonary artery occlusion pressure decay curves
allow for an identification and quantification of increased
distal small arteries and arterioles resistance.
Marie-The´re`se Gautier helped in the preparation of this report.
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